Hemostasis is how the body stops bleeding. For a phlebotomist, it's also the reason half of your tube colors exist. Sodium citrate, EDTA, and even the warming requirement for serum tubes all trace back to whether you want the blood to clot or not, and which step of the cascade you want to interrupt. Once you understand the three phases of hemostasis, the order of draw stops being a memorized list and starts feeling like cause and effect.
The NHA CPT, ASCP PBT, AMT RPT, and NCCT NCPT all test hemostasis under the umbrella of anatomy and physiology. You won't be asked to draw the cascade from scratch, but you will be asked why a citrate tube can't be short-filled, why warfarin patients need PT/INR monitoring, and which factor is deficient in hemophilia A. The questions are predictable once you know the framework.
The Three Phases of Hemostasis
When a vessel is injured, the body responds in three overlapping steps. They start within seconds of the damage and run in parallel for the first few minutes.
Phase 1: Vascular Spasm (Vasoconstriction)
The instant a vessel is cut or punctured, the smooth muscle in the vessel wall contracts. The lumen narrows, blood flow to the injured area drops, and the pressure pushing blood out of the wound decreases. This is the fastest response, lasting seconds to minutes. It buys time for the slower platelet and coagulation responses to catch up.
Vasoconstriction is local. The injured segment clamps down while surrounding vessels stay normal. For a venipuncture, this is part of why holding pressure on the site after needle removal works so well: you're mechanically reinforcing what the vessel is already trying to do.
Phase 2: Platelet Plug Formation (Primary Hemostasis)
This is the platelet response. When the vessel wall is damaged, the underlying collagen and the endothelial cells release von Willebrand factor (vWF). vWF acts as a bridge. It binds to exposed collagen on one side and to receptors on circulating platelets on the other side. Platelets adhere to the injury site.
Once stuck, platelets activate. They change shape from smooth discs into spiky, sticky cells. They release ADP, thromboxane A2, and serotonin, which recruit more platelets and amplify the response. Activated platelets express GP IIb/IIIa receptors that bind fibrinogen, and through fibrinogen they bind to each other. This is aggregation. Within a few minutes, a soft platelet plug fills the wound.
A platelet plug alone isn't strong enough to hold against arterial pressure for long. It needs to be reinforced with fibrin. That's where the cascade comes in.
For phlebotomy, primary hemostasis is what determines bleeding time and whether a patient stops bleeding at the puncture site. Patients with low platelet counts (thrombocytopenia) or platelets that don't function well (von Willebrand disease, aspirin therapy, clopidogrel) bleed longer at venipuncture sites. You may be asked to hold pressure for 5 minutes or more on these patients instead of the usual 1 to 2.
Phase 3: Coagulation Cascade (Secondary Hemostasis)
The cascade is a chain reaction of plasma proteins called clotting factors. Each factor activates the next in line. The end product is fibrin, a tough, insoluble protein that weaves through the platelet plug and locks it in place. Without fibrin reinforcement, the plug falls apart at the first sign of pressure.
The cascade has three branches: the intrinsic pathway, the extrinsic pathway, and the common pathway where the two converge.
Clotting Factors and the Pathways
There are 13 clotting factors, numbered with Roman numerals. Factor VI was reclassified out of existence decades ago, so the active list is I, II, III, IV, V, VII, VIII, IX, X, XI, XII, XIII. You don't need every factor memorized for the exam, but a handful matter clinically.
| Factor | Common Name | Notable Detail |
|---|---|---|
| I | Fibrinogen | Cleaved into fibrin at the end of the cascade |
| II | Prothrombin | Becomes thrombin in the common pathway. Vitamin K dependent. |
| III | Tissue Factor | Released by damaged tissue. Triggers the extrinsic pathway. |
| IV | Calcium (Ca2+) | Required at multiple steps. Citrate and EDTA both bind it. |
| VII | Proconvertin | Extrinsic pathway. Vitamin K dependent. Shortest half-life. |
| VIII | Antihemophilic factor A | Deficient in hemophilia A. Intrinsic pathway. |
| IX | Christmas factor | Deficient in hemophilia B. Vitamin K dependent. |
| X | Stuart-Prower factor | Common pathway entry point. Vitamin K dependent. |
The Extrinsic Pathway
Triggered by tissue damage outside the blood vessel. Damaged cells release tissue factor (factor III), which combines with factor VII. The tissue factor / VIIa complex activates factor X, dropping into the common pathway. This pathway is fast. It can produce fibrin in about 15 seconds in vivo.
The PT (prothrombin time) and the derived INR (International Normalized Ratio) measure the extrinsic and common pathways. PT is what you monitor in patients on warfarin.
The Intrinsic Pathway
Triggered by contact with a negatively charged surface inside the vessel, like exposed collagen or a glass test tube. Factor XII activates first, then XI, then IX, then VIII. Factor VIIIa joins IXa to activate factor X. Slower than the extrinsic pathway, taking several minutes in vivo.
The aPTT (activated partial thromboplastin time), sometimes just called PTT, measures the intrinsic and common pathways. aPTT is what you monitor in patients on heparin and what's used to screen for hemophilia A and B.
The Common Pathway
Both pathways converge on factor X. Activated Xa, with factor V, calcium, and phospholipid as cofactors, converts prothrombin (II) to thrombin (IIa). Thrombin then cleaves fibrinogen (I) into fibrin monomers, which polymerize. Factor XIII cross-links the polymers into a stable fibrin mesh.
If you remember nothing else: thrombin is the kingpin enzyme, fibrinogen is the substrate, and fibrin is the finished clot.
Vitamin K and Calcium: Why They Matter at the Tube
Four factors require vitamin K for the liver to synthesize them in active form: II, VII, IX, and X. A common memory hook is 1972 read out as the years (II, VII, IX, X). Vitamin K antagonists like warfarin (Coumadin) block the recycling of vitamin K, so the liver makes inactive versions of these four factors. PT/INR rises. The patient bleeds more easily. This is therapeutic in atrial fibrillation, mechanical valves, and DVT prophylaxis.
Calcium (factor IV) is needed at multiple steps in the cascade. Both branches require it for factor X activation, and the common pathway needs it to convert prothrombin to thrombin. Take calcium out of the picture and the cascade stops.
This is exactly what your tubes do.
- Sodium citrate (light blue) binds calcium reversibly. The 9:1 blood-to-citrate ratio is calibrated so the lab can re-add calcium in measured amounts and time how long the cascade takes to complete. That's the PT and aPTT.
- EDTA (lavender) binds calcium tightly and irreversibly. The clot pathway is shut down completely. Used for the CBC because you want cells preserved in their natural state without any clotting interfering with the count.
- Heparin (green) works differently. It activates antithrombin III, which then inactivates thrombin and factor Xa. No calcium chelation. Used for plasma chemistry tests where you need anticoagulation without removing calcium (which would skew the calcium result).
Understanding this is why citrate ratio matters so much. If a citrate tube is short-filled, there's too much citrate per milliliter of blood. The lab adds back the standard amount of calcium during testing, but the citrate keeps binding it. The cascade can't start on time, and PT and aPTT come back falsely prolonged. The patient gets flagged as a bleeder when they're actually fine. CLSI requires citrate tubes to be filled to at least 90% of the indicated volume. Anything below that gets rejected.
Fibrinolysis: Cleaning Up
Once the wound heals, the body needs to dissolve the clot. This is fibrinolysis. The key enzyme is plasmin, which is made from its inactive precursor plasminogen. Tissue plasminogen activator (tPA) is the trigger. tPA is also the active ingredient in clot-busting drugs given for stroke and pulmonary embolism.
Plasmin chops fibrin into fibrin degradation products (FDPs). One specific fragment is D-dimer, which only appears when cross-linked fibrin is broken down. That makes D-dimer a useful marker for active clotting and clot dissolution. Elevated D-dimer suggests DVT, PE, or DIC. A normal D-dimer in a low-risk patient effectively rules out DVT and PE without imaging.
D-dimer is collected in a light blue citrate tube. Same ratio rules apply.
Coagulation Tests You'll See on Requisitions
| Test | Tube | Measures | Common Use |
|---|---|---|---|
| PT / INR | Light blue | Extrinsic + common | Warfarin monitoring |
| aPTT (PTT) | Light blue | Intrinsic + common | Heparin monitoring, hemophilia screen |
| Fibrinogen | Light blue | Factor I level | DIC, liver disease workup |
| D-dimer | Light blue | Cross-linked fibrin breakdown | DVT/PE rule-out, DIC |
| Platelet count | Lavender (EDTA) | Number of platelets per microliter | Bleeding workup, chemo monitoring |
| Bleeding time | None (in vivo test) | Primary hemostasis | Largely replaced by PFA-100 |
Note that platelet count goes in EDTA, not citrate. Different lab, different mechanism. EDTA preserves platelet morphology for the automated analyzer and the smear. Citrate would interfere with the cell counter's readings.
Conditions That Affect Hemostasis
You'll see these patients regularly. Knowing what each condition does helps you anticipate longer hold times, special handling, or extra inversions.
- Hemophilia A: Factor VIII deficiency. X-linked recessive, mostly affects males. Prolonged aPTT, normal PT. Treated with factor VIII concentrate.
- Hemophilia B (Christmas disease): Factor IX deficiency. Also X-linked. Same lab pattern as hemophilia A. Treated with factor IX concentrate.
- Von Willebrand disease: Most common inherited bleeding disorder. vWF deficiency or dysfunction. Affects platelet adhesion. Variable lab findings.
- Warfarin therapy: Vitamin K antagonist. Targets factors II, VII, IX, X. Monitored by PT/INR. Therapeutic INR is usually 2.0 to 3.0, higher for mechanical valves.
- Heparin therapy: Activates antithrombin III. Monitored by aPTT for unfractionated heparin. Low-molecular-weight heparin (enoxaparin) usually doesn't need monitoring.
- DOACs (apixaban, rivaroxaban, dabigatran): Direct oral anticoagulants. Don't require routine monitoring, but PT and aPTT may be mildly prolonged.
- Thrombocytopenia: Low platelet count, below 150,000/uL. Common in chemo patients, ITP, and liver disease. Plan for longer hold times.
- Liver disease: The liver makes most clotting factors. Severe disease causes prolonged PT and aPTT. Hold pressure longer.
- DIC (disseminated intravascular coagulation): Pathologic activation of clotting throughout the vasculature. Consumes factors and platelets. Elevated D-dimer, low fibrinogen, low platelets, prolonged PT and aPTT.
Pre-Analytical Errors That Tank Coag Testing
A coag tube has more ways to go wrong than almost any other tube. Here's what to watch for.
Short fill. Already covered, but worth repeating. Below 90% fill means rejection. With a butterfly, draw a discard tube first to clear dead-space air before filling the light blue.
Clot in the tube. Inadequate mixing. Citrate tubes need 3 to 4 gentle inversions immediately after the draw. If the blood sits without mixing, the additive can't work fast enough and a clot forms before the tube reaches the lab. A clotted coag tube is rejected.
EDTA carryover. Light blue must be drawn before lavender in the order of draw. EDTA chelates calcium more aggressively than citrate, so even a tiny carryover binds extra calcium and falsely prolongs PT and aPTT.
Hemolysis. Hemolyzed samples release intracellular components that can interfere with optical clot detection. Visibly pink or red plasma usually means redraw.
Wrong patient ID, missing labels, or unsigned requisition. Coag tubes get rejected on labeling errors with no recourse. Confirm the patient and label at the bedside.
Clinical Scenarios
Scenario 1: A phlebotomist draws a light blue citrate tube on a patient using a butterfly. The patient has small veins and the draw is slow. The tube fills to about 70% of the indicated volume. The phlebotomist sends it to the lab. What happens?
Show Answer
Answer: The tube will be rejected for inadequate fill. CLSI requires citrate tubes to be filled to at least 90% of the indicated volume. At 70% fill, the citrate-to-blood ratio is too high, which over-chelates calcium during the assay and produces falsely prolonged PT and aPTT results. The correct action is to recognize the short fill at the chairside, document the slow draw, and recollect the tube. With a butterfly, drawing a small discard tube first to clear the tubing dead space helps prevent this.
Scenario 2: A 68-year-old patient on warfarin for atrial fibrillation is in the lab for routine monitoring. The order is for PT/INR. Which pathway does this test evaluate, and which clotting factors does warfarin affect?
Show Answer
Answer: PT/INR evaluates the extrinsic and common pathways. Warfarin is a vitamin K antagonist and reduces the active levels of factors II, VII, IX, and X. Of those, factor VII has the shortest half-life and falls first, which is what the PT primarily detects. The therapeutic INR for atrial fibrillation is typically 2.0 to 3.0. The tube is light blue sodium citrate, drawn second in the order of draw, filled to at least 90%, and inverted 3 to 4 times.
Scenario 3: A 6-year-old boy with a known history of hemophilia A is in the outpatient lab for a factor VIII level. After the venipuncture, what should the phlebotomist do differently compared to a routine pediatric draw?
Show Answer
Answer: Hold pressure on the puncture site for an extended period, often 5 to 10 minutes or longer, until bleeding has fully stopped. Hemophilia A is a factor VIII deficiency that impairs the intrinsic pathway and secondary hemostasis. The platelet plug forms normally but isn't reinforced with fibrin in a timely manner, so bleeding can recur after pressure is released. Confirm the site is dry before applying a bandage, and instruct the caregiver to watch for late bleeding or bruising.
Scenario 4: A patient's aPTT comes back significantly prolonged. The PT is normal. The patient is not on any anticoagulant. Which pathway is implicated, and what conditions could explain this?
Show Answer
Answer: An isolated prolonged aPTT with a normal PT points to a defect in the intrinsic pathway. Possible causes include hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), factor XI deficiency, von Willebrand disease (which can also affect platelet function), or a lupus anticoagulant. A pre-analytical cause should be ruled out first: short fill, clotted tube, or EDTA carryover from incorrect order of draw.
Key Takeaways
- Hemostasis runs in three phases: vasoconstriction, platelet plug formation, and the coagulation cascade.
- Primary hemostasis is platelet-driven and depends on vWF, adhesion, activation, and aggregation.
- Secondary hemostasis is the cascade. Extrinsic + common = PT/INR. Intrinsic + common = aPTT.
- Vitamin K dependent factors are II, VII, IX, X. Warfarin blocks them.
- Calcium (factor IV) is required throughout. Citrate and EDTA both work by binding calcium.
- Citrate tubes need a strict 9:1 ratio. Short fill = rejection.
- EDTA must come after light blue in the order of draw to prevent calcium-binding carryover.
- Fibrinolysis dissolves clots via plasmin. D-dimer is the breakdown marker.
- Patients on anticoagulants, with hemophilia, or with thrombocytopenia need longer post-draw pressure.